TWiV clinical update with Dr. Daniel Griffin

In his weekly clinical update Dr. Griffin discusses monkeypox infection in humans across 16 countries, pregnancy outcomes after SARS-CoV-2 infection by trimester, vaccination intent and belief, antiviral drug treatment for non-severe disease, the association of smoking with infected hospitalized patients, the association of Paxlovid on negative conversion rates among high-risk patients with COVID-19, safety and efficacy of Molnupiravir, usage of enoxaparin for primary thromboprophylaxis, statin and aspirin as therapy in infected patients, post-COVID-19 conditions among children 90 days after SARS-CoV-2 Infection, and symptoms and risk factors for long COVID in non-hospitalized adults.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Monkeypox infection in humans (NEJM)
• Pregnancy outcomes after infection (PLOS ONE)
• Vaccination intent and belief (Emerging Infectious Diseases)
• Antiviral drug treatment for non-severe disease (CMAJ)
• Smoking association with infected hospitalized patients (PLOS ONE)
• Impact of Paxlovid on negative conversion rates (CID)
• PAXLOVID patient eligibility screening checklist (FDA)
• Remdesivir fact sheet for providers (Veklury)
• Bebtelovimab fact sheet for providers (FDA)
• Safety and efficacy of Molnupiravir (Journal of Medical Virology)
• Enoxaparin for primary thromboprophylaxis (OVID)
• Statin and aspirin as therapy in infected patients (BMC)
• Post-infection conditions among children (JAMA)
• Symptoms and risk factors for long-term effects (Nature Medicine)
• Contribute to FIMRC fundraiser at PWB
• Dr. Griffin’s treatment guide (pdf)
• Letters read on TWiV 922
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to daniel@microbe.tv